<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904590</url>
  </required_header>
  <id_info>
    <org_study_id>INFEII</org_study_id>
    <nct_id>NCT02904590</nct_id>
  </id_info>
  <brief_title>A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease</brief_title>
  <acronym>INFEII</acronym>
  <official_title>A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the incidence and risk factors related to Infection
      in patients with Inflammatory Bowel Disease (IBD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IBD could lead to an increased risk of infections, particularly related to immunosuppressive
      therapy. The true effect of having IBD in the development of infections has not been studied
      in depth since the cohort studies are scarce and the results of studies with different
      approaches are contradictory.

      The limited time period of former studies may not be enough to assess infectious
      complications that may occur in a long term period.

      Moreover, certain polymorphisms demonstrated to confer a higher risk of opportunistic
      infections under immunosuppressive conditions, for instance HIV, patients with cystic
      fibrosis and Candida' infections. For this reason, it seems reasonable to think that genetic
      factors might play a role in the risk of opportunistic infections in IBD.

      The hypothesis of this study is that patients with IBD have an increased risk of infection by
      immunosuppressive treatment.

      TYPE OF STUDY Prospective cohort study that evaluates the effect of immunosuppression and
      other clinical factors in the onset of infection in IBD

      STUDY DESIGN PATIENTS &amp; METHODS This study is aimed to all incidental patients diagnosed with
      Crohn's disease and ulcerative colitis included in the ENEIDA database.

      METHODS An infection would be considered as relevant when: 1) requires hospital admission, 2)
      leads to death or endangers the patient's life (ICU admission, presence of hemodynamic
      instability, sepsis, tracheal intubation, vasoactive drug requirement), 3) must be treated
      with specific antibiotics (antibacterials, antivirals, antifungals) 4) affects recurrently
      (herpes virus, papilloma virus, etc). 5) requires change/withdrawal of immunosuppressive or
      biological treatment.

      The appearance of relevant infection will be prospectively evaluated, performing a
      subanalysis at 3 and 5 years using ENEIDA platform. ENEIDA is a database from a Spanish
      national study in IBD on genetic and environmental determinants run under GETECCU (Grupo
      Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa) supervision. This database
      basically comprises: demographic characteristics, type of IBD, immunosuppressant treatment,
      biological treatment or surgery)

      At the time of inclusion the following variables should be available (and are mandatory):
      demographic characteristics, type of IBD, date of diagnosis, phenotypic characteristics of
      the disease, history of serious infections, information on received treatments particularly
      the exposure to immunosuppressants, biological treatment or surgery and whether an infection
      has occurred as a complication of the three treatment groups. It should also be collected the
      following serologic details: hepatitis type B virus C, HIV, tuberculosis (TB), varicella
      zoster status.

      At the time of registration a blood sample (10cc) will be drawn and sent to a biobank to
      analyze the DNA for genetic research.

      STUDY ANALYSIS Sample calculation

      The main objective of this study is to determine the percentage of infections in IBD and the
      related risk factors for the development of infections in patients with IBD. Given that the
      reported prevalence of infection varies between 6 and 10%the formula for estimating endless
      samples, establishing:

        -  Security level of the confidence interval at 95%

        -  Expected value for the worst case scenario of 6% (prevalence of infection)

        -  Precision of 1.5%

        -  The minimum sample number is set to 963, and assuming a loss rate of 20%

      With these assumptions, the total number of patients to be included is 1204 patients.

      The statistical analysis will be in three steps: (1) independent clinical factors analysis,
      (2) genetic factors infection-related analysis and (3) clinical and genetic factors
      infection- related analysis.

      Baseline and follow up data will be compared among patients who develop infection and those
      who do not. Quantitative variables will be contrast by T-student and Mann-Whitney test.
      Qualitative variable will be contrast by X2 or Fisher test. Logistic regression will be
      conducted to analyze independent associations between variables and Kaplan-Meier test to
      calculate survival curves.

      An analysis of Cox proportional hazards will be conducted to assess the effect of exposure to
      independent predictors of the risk of significant infection or mortality.

      Finally the intensity of the significant associations will be measured by calculating the OR,
      HR and confidence interval of 95%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>The incidence of infection and type of infection in patients with ulcerative colitis and Crohn's disease, regardless of treatment received. ulcerative colitis and Crohn's disease, regardless of treatment received.</measure>
    <time_frame>Change from baseline incidence and type of infection at 3 and 5 years</time_frame>
    <description>Serious infection means any untoward medical occurrence that at any dose:
Results in death or life-threatening
Requires in patient hospitalization or prolongation of an existing hospitalization
Is a medically important event.
Requires specific chemotherapy treatment
Emerges repeatedly.
Induces a switch or a withdrawal of the immunosuppressive or biological treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical, demographic, epidemiologic and genetic factors associated with the risk of infection in patients with IBDassociated with the risk of infection in patients with IBD.</measure>
    <time_frame>Change from baseline and at 3 and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of duration and immunosuppressive potency in the development of infections</measure>
    <time_frame>at baseline and at 3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of infection on morbidity and mortality in patients with IBD.</measure>
    <time_frame>at baseline and at 3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The type of infections in IBD patients grouped by systems and whether they are opportunistic or not.</measure>
    <time_frame>at baseline and at 3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1204</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>IBD patients</arm_group_label>
    <description>Incidental patients with IBD controlled (including Crohn's disease, Ulcerative colitis and unclassified colitis)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample of 10 cc
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Incident cases of IBD registered on ENEIDA data base
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  All incidental patients with IBD controlled at each participating center, registered
             in the ENEIDA database could be included, until the expected study sample is reached
             (n=1204 patients).

          -  An incidental IBD case is any patient with a diagnosis of Crohn's disease, ulcerative
             colitis and unclassified colitis after 3-6 month of the conclusive diagnosis of IBD.

        Exclusion Criteria:

          -  HIV infection or any congenital immunodeficiency at the time of inclusion.

          -  To be under any immunosuppressant therapy for another reason other than IBD at IBD
             diagnosis.

          -  No consent to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yamile Zabana</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Casas</last_name>
    <phone>635 899 553</phone>
    <email>secretariacientifica2@geteccu.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yamile Zabana</last_name>
    <email>yzabana@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sabino Riestra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eugeni Domenech, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>VICTOJ J MORALES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jordi Guardiola, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Althaia, xarxa assistencial universitaria de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jordina Llaó, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>XAVIER CALVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MERCÈ NAVARRO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Esteve, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Bilbao</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>JOSE LUIS CABRIADA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MONTSE RIVERO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Tomelloso</name>
      <address>
        <city>Tomelloso</city>
        <state>Ciudad REAL</state>
        <zip>13700</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfredo J Lucendo Villarín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>FERNANDO BERMEJO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofía</name>
      <address>
        <city>San Sebastián De Los Reyes</city>
        <state>Madrid</state>
        <zip>28703</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>RAMON PAJARES VILLAROYA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospital Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>LUISA DE CASTRO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Esther García-Planella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MONTSERRAT ANDREU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>VALLE GARCÍA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David BUSQUETS CASALS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>XAVIER ALDEGUER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>EVA SESÉ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Pérez-Gisbert, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci hospitalari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MARTA PIQUERAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PILAR NOS MATEU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de València</name>
      <address>
        <city>València</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MIGUEL MÍNGUEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>FERNANDO GOMOGLLÓN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013 Aug;108(8):1268-76. doi: 10.1038/ajg.2013.138. Epub 2013 May 7.</citation>
    <PMID>23649185</PMID>
  </reference>
  <reference>
    <citation>Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr;134(4):929-36. doi: 10.1053/j.gastro.2008.01.012. Epub 2008 Jan 11.</citation>
    <PMID>18294633</PMID>
  </reference>
  <reference>
    <citation>Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. Erratum in: Clin Gastroenterol Hepatol. 2006 Jul;4(7):931.</citation>
    <PMID>16678077</PMID>
  </reference>
  <reference>
    <citation>Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep;107(9):1409-22. doi: 10.1038/ajg.2012.218. Epub 2012 Aug 14.</citation>
    <PMID>22890223</PMID>
  </reference>
  <reference>
    <citation>Beaugerie L, Gerbes AL. Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear? Gut. 2010 Oct;59(10):1310-1. doi: 10.1136/gut.2010.217331.</citation>
    <PMID>20833661</PMID>
  </reference>
  <reference>
    <citation>Papadopoulos AI, Ferwerda B, Antoniadou A, Sakka V, Galani L, Kavatha D, Panagopoulos P, Poulakou G, Protopapas K, van der Meer JW, Netea MG, Giamarellos-Bourboulis EJ. Association of Mal/TIRAP S180L variant polymorphism with decreased infection risk in patients with advanced HIV-1 infection. Cytokine. 2012 Oct;60(1):104-7. doi: 10.1016/j.cyto.2012.05.008. Epub 2012 Jun 8.</citation>
    <PMID>22683004</PMID>
  </reference>
  <reference>
    <citation>Radovanovic I, Mullick A, Gros P. Genetic control of susceptibility to infection with Candida albicans in mice. PLoS One. 2011 Apr 20;6(4):e18957. doi: 10.1371/journal.pone.0018957.</citation>
    <PMID>21533108</PMID>
  </reference>
  <reference>
    <citation>Papadopoulos AI, Ferwerda B, Antoniadou A, Sakka V, Galani L, Kavatha D, Panagopoulos P, Poulakou G, Kanellakopoulou K, van der Meer JW, Giamarellos-Bourboulis EJ, Netea MG. Association of toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms with increased infection risk in patients with advanced HIV-1 infection. Clin Infect Dis. 2010 Jul 15;51(2):242-7. doi: 10.1086/653607.</citation>
    <PMID>20521908</PMID>
  </reference>
  <reference>
    <citation>Pine SO, McElrath MJ, Bochud PY. Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS. 2009 Nov 27;23(18):2387-95. doi: 10.1097/QAD.0b013e328330b489.</citation>
    <PMID>19855253</PMID>
  </reference>
  <reference>
    <citation>Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J Clin Microbiol. 2003 Jan;41(1):90-6.</citation>
    <PMID>12517831</PMID>
  </reference>
  <reference>
    <citation>Connelly TM, Sehgal R, Berg AS, Hegarty JP, Deiling S, Stewart DB, Poritz LS, Koltun WA. Mutation in TAGAP is protective of anal sepsis in ileocolic Crohn's disease. Dis Colon Rectum. 2012 Nov;55(11):1145-52. doi: 10.1097/DCR.0b013e3182676931.</citation>
    <PMID>23044675</PMID>
  </reference>
  <reference>
    <citation>Obrador A, López San Román A, Muñoz P, Fortún J, Gassull MA; Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis]. Gastroenterol Hepatol. 2003 Jan;26(1):29-33. Review. Spanish.</citation>
    <PMID>12525326</PMID>
  </reference>
  <reference>
    <citation>Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, Penninckx F, Vermeire S, Rutgeerts P. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004 Mar;10(2):73-8.</citation>
    <PMID>15168804</PMID>
  </reference>
  <reference>
    <citation>Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009 Apr;58(4):501-8. doi: 10.1136/gut.2008.163642. Epub 2008 Oct 2.</citation>
    <PMID>18832524</PMID>
  </reference>
  <reference>
    <citation>Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.</citation>
    <PMID>20393175</PMID>
  </reference>
  <reference>
    <citation>Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582.</citation>
    <PMID>23128233</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBD</keyword>
  <keyword>Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

